99 research outputs found

    Fenoldopam use in a burn intensive care unit: a retrospective study

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Fenoldopam mesylate is a highly selective dopamine-1 receptor agonist approved for the treatment of hypertensive emergencies that may have a role at low doses in preserving renal function in those at high risk for or with acute kidney injury (AKI). There is no data on low-dose fenoldopam in the burn population. The purpose of our study was to describe our use of low-dose fenoldopam (0.03-0.09 μg/kg/min) infusion in critically ill burn patients with AKI.</p> <p>Methods</p> <p>We performed a retrospective analysis of consecutive patients admitted to our burn intensive care unit (BICU) with severe burns from November 2005 through September 2008 who received low-dose fenoldopam. Data obtained included systolic blood pressure, serum creatinine, vasoactive medication use, urine output, and intravenous fluid. Patients on concomitant continuous renal replacement therapy were excluded. Modified inotrope score and vasopressor dependency index were calculated. One-way analysis of variance with repeated measures, Wilcoxson signed rank, and chi-square tests were used. Differences were deemed significant at p < 0.05.</p> <p>Results</p> <p>Seventy-seven patients were treated with low-dose fenoldopam out of 758 BICU admissions (10%). Twenty (26%) were AKI network (AKIN) stage 1, 14 (18%) were AKIN stage 2, 42 (55%) were AKIN stage 3, and 1 (1%) was AKIN stage 0. Serum creatinine improved over the first 24 hours and continued to improve through 48 hours (<it>p </it>< 0.05). There was an increase in systolic blood pressure in the first 24 hours that was sustained through 48 hours after initiation of fenoldopam (<it>p </it>< 0.05). Urine output increased after initiation of fenoldopam without an increase in intravenous fluid requirement (<it>p </it>< 0.05; <it>p </it>= NS). Modified inotrope score and vasopressor dependency index both decreased over 48 hours (<it>p </it>< 0.0001; <it>p </it>= 0.0012).</p> <p>Conclusions</p> <p>These findings suggest that renal function was preserved and that urine output improved without a decrease in systolic blood pressure, increase in vasoactive medication use, or an increase in resuscitation requirement in patients treated with low-dose fenoldopam. A randomized controlled trial is required to establish the efficacy of low-dose fenoldopam in critically ill burn patients with AKI.</p

    FIELD DEMONSTRATION OF A MEMBRANE PROCESS TO RECOVER HEAVY HYDROCARBONS AND TO REMOVE WATER FROM NATURAL GAS

    No full text
    The objective of this project is to design, construct and field demonstrate a 3-MMscfd membrane system to recover natural gas liquids (NGL) and remove water from raw natural gas. An extended field test to demonstrate system performance under real-world conditions is required to convince industry users of the efficiency and reliability of the process. The system will be designed and fabricated by Membrane Technology and Research, Inc. (MTR) and then installed and operated at British Petroleum (BP)-Amoco's Pascagoula, MS plant. The Gas Research Institute will partially support the field demonstration and BP-Amoco will help install the unit and provide onsite operators and utilities. The gas processed by the membrane system will meet pipeline specifications for dewpoint and Btu value and can be delivered without further treatment to the pipeline. Based on data from prior membrane module tests, the process is likely to be significantly less expensive than glycol dehydration followed by propane refrigeration, the principal competitive technology. At the end of this demonstration project the process will be ready for commercialization. The route to commercialization will be developed during this project and may involve collaboration with other companies already servicing the natural gas processing industry. Document type: Repor
    • …
    corecore